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1. Introduction  
Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of unknown 
etiology.  The onset of SLE is believed to be triggered by ill-defined environmental factors in 
genetically susceptible individuals (Mok, 2003a).  Although the exact pathogenetic 
mechanisms have yet to be elucidated, recent works have revealed a myriad of 
immunological abnormalities in patients with SLE. These include aberrant apoptosis and 
defective clearance of apoptotic materials such as nuclear autoantigens and nucleosomes, 
and immune complexes by macrophages and the complement system (Katsiari, 2010), 
increased maturation of myeloid dendritic cells which drive the development of the 
proinflammatory Th17 cells (Fransen, 2010), and defective functions of the regulatory T cells 
(Tregs) leading to hyperactivity of the helper T cells and autoreactive B cells causing 
production of autoantibodies (Tucci, 2010). 
Of the numerous clinical manifestations of SLE, renal disease is one of the commonest and 
most serious.  Lupus renal disease appears to be more prevalent in certain ethnic groups 
such as the African and Hispanic Americans, as well as the Asians (Mok, 2005a). Renal 
involvement in SLE adversely affects its ultimate prognosis as reflected by the rates of 
patient survival and renal survival (survival without the need for renal replacement 
therapy), and is a major determinant for morbidity and impairment of quality of life (Mok, 
1999).  
The glomerulus is the commonest site of kidney involvement by lupus. However, the renal 
interstitium and tubules, as well as the vessels may also be affected (Cross, 2005). The 
presentation of renal disease in SLE is variable, ranging from no symptoms, trace 
proteinuria or urinary sediments to frank nephrotic syndrome, chronic renal insufficiency, 
and nephritic syndrome with rapid progression leading to acute renal failure. Early 
recognition of renal disease and close monitoring of renal parameters for progress after 
treatment is an essential part of the management. Conventional serological markers and 
clinical renal parameters for active lupus nephritis are not sensitive or specific enough, and 
novel biomarkers for early detection of renal disease and prediction of renal prognosis are 
under ongoing evaluation. It is believed that a combination of conventional parameters with 
one or more serological or urine biomarkers may yield better sensitivity and specificity for 
predicting renal activity or flare of nephritis in patients with SLE. This may help to abate the 
need for more invasive investigations such as renal biopsy in the assessment of renal activity 
and allow early institution of therapy (Mok, 2010a). 
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Therapy of lupus nephritis should target at symptomatic control, preservation of renal 
function, reduction of renal flares, prevention of treatment-related complications, and 
ultimately reduction in mortality (Mok, 2003b). The treatment schedule of lupus nephritis 
is now divided into an induction phase and a maintenance phase. Induction treatment 
aims at controlling inflammation and minimizing glomerular injury, whereas 
maintenance therapy is to reduce the risk of renal flares and renal function decline in the 
long-run. A combination of glucocorticoids with a non-glucocorticoid immunosuppressive 
agent has been shown to be more effective than glucocorticoid monotherapy in reducing 
the risk of progression into end stage renal failure in lupus nephritis (Austin, 1986). Of the 
many non-glucocorticoid immunomodulating agents, mycophenolate mofetil (MMF)  
has emerged to be the first-line treatment of lupus nephritis around the world because 
studies have shown that it is associated with fewer adverse effects than 
cyclophosphamide, particularly on the ovarian functions (Ginzler, 2005). Recent evidence 
also reveals that maintenance therapy with MMF is more effective than azathioprine in 
reducing the composite endpoint of renal flare and deterioration of renal function 
(Wolfsy, 2010). 
In this chapter, the prevalence, presentation and significance of renal involvement in 
patients with SLE is discussed. An update on the current therapies of lupus nephritis is 
also presented based on the results of recent randomized controlled trials. Finally, 
promising biomarkers for the detection and monitoring of lupus nephritis is briefly 
reviewed. 
2. Prevalence of renal disease in SLE 
Lupus renal disease appears to be more prevalent in certain ethnic groups such as the 
African and Hispanic Americans, as well as the Asians (Mok, 2005a; Dooley, 1997). In a 
comparative study of the clinical manifestations of SLE in three ethnic groups, it was 
reported that renal disease, as defined by the American College of Rheumatology (ACR) 
criteria, namely persistent daily proteinuria of more than 500mg, presence of cellular casts 
or biopsy evidence of lupus nephritis, occurred in 45% of African American, 42% of Chinese 
and 30% of Caucasian patients, respectively (Mok, 2005a).  Another multi-ethnic US cohort 
of SLE patients reported that renal disease occurred in 51% of Africans and 43% of 
Hispanics but only in 14% of Caucasians (Bastian, 2002). In a prospective study of 216 
Chinese patients with new onset SLE, 31% patients had active renal disease at the time of 
initial presentation (Mok, 2004). Of 148 patients without overt renal disease at SLE onset, 
33% developed active renal disease after a median of 14 months. The overall cumulative 
incidence of renal disease as defined according to the ACR renal criteria in this cohort of 
patients was 60% at 5 years post-SLE diagnosis (Mok, 2004). The actual incidence of renal 
disease might have been underestimated as the renal definition does not include subtle renal 
involvement such as proteinuria of less than 500mg/day or microscopic hematuria, or both. 
These studies illustrate that lupus renal involvement is more common in the Africans, 
Hispanics and Chinese than the Caucasians. 
3. Clinical presentation of lupus renal disease 
The presentation of renal disease in SLE is variable, ranging from no symptoms (detected by 
routine renal biopsy or “silent” lupus nephritis), trace proteinuria or active urinary 
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sediments (microscopic hematuria, pyuria or cellular casts), to more serious proteinuria 
(nephrotic syndrome), and acute nephritic syndrome with rapid progression to acute renal 
failure. Occasionally, patients may present with chronic renal failure, isolated renal 
insufficiency and hypertension as the initial manifestation.  
The wide range of presentations of lupus nephritis does not necessarily correlate with the 
histological findings from renal biopsy. “Silent” lupus nephritis has long been recognized in 
the literature. A retrospective study of 21 SLE patients with low level of proteinuria 
(<1gm/day) who underwent renal biopsy showed that proliferative lupus nephritis was 
present in 57% patients (Christopher-Stine, 2007). This emphasizes the frequent discordance 
of the histological severity with clinical presentation, and the need for renal biopsy, 
especially for new onset renal disease as evidenced by abnormal urinalysis and/or renal 
function impairment. 
4. Renal biopsy 
Renal biopsy is the gold standard of confirming the diagnosis of lupus glomerulonephritis. 
The finding of positive staining for immunoglobulin G, A and M, together with C1q, C3 and 
C4, constitutes the “full house” staining pattern for lupus nephritis. In addition to 
establishment of the diagnosis of lupus renal disease and confirming renal flares, renal 
biopsy also provides information on the histological classes of lupus nephritis, and the 
degree of inflammation and damage in the kidneys so as to guide therapeutic decision. 
Renal biopsy should be considered in SLE patients with new onset of proteinuria of more 
than 1g/day with and without active urinary sediments, especially in the presence of active 
lupus serology or impaired renal function. Some experts recommend renal biopsy at a lower 
threshold of proteinuria (eg. 500mg/day). 
Patients with lupus nephritis that is refractory to treatment should be evaluated for other 
possible causes for the persistence of proteinuria or deterioration in renal function such as 
the nephrotoxic side effects of medications (eg. the calcineurin inhibitors and non-
steroidal anti-inflammatory drugs), renal vein thrombosis, infections, overdiuresis and 
poorly controlled hypertension. Treatment compliance should be checked. A repeat renal 
biopsy should be considered in patients with persistently active serological markers 
because it provides information on the following: (1) histological transformation of the 
classes of lupus nephritis; (2) the degree of residual activity in the kidneys; and (3) the 
extent of chronic irreversible changes and its progression since the initiation  
of immunosuppressive treatment. These data may help to guide further treatment 
decisions. 
5. Histological classification of lupus glomerulonephritis 
The histological classification of lupus nephritis has undergone several modifications. The 
first WHO classification was formulated in 1974 and was last revised in 1995. According to 
this system, lupus glomerulonephritis was classified according to the extent and pattern of 
immune deposits and inflammation, which were detected by immunohistochemistry on 
light microscopy. There were 5 histological subtypes of lupus nephritis (class I to V) in the 
1974 WHO classification (McCluskey, 1975).  The differentiation of class III and class IV 
disease was based on the percentage of glomeruli affected by proliferative lesions (>50% 
was classified as Class IV). No qualitative differences between class III and class IV lesions 
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were described. Tubulointerstitial and vascular lesions were not included in the 
classification. 
The WHO classification was revised in 1982 (Churg, 1982). Class I disease was subdivided 
into 2 subclasses based on the presence and absence of immune deposits on 
immunofluorescence or electron microscopy. Class III was denoted focal segemental 
glomerulonephritis and Class IV was referred to diffuse proliferative glomerulonephritis. 
There were no description on the percentage of involvement of glomeruli for the 
differentiation between class III and class IV disease. Class III and IV disease was 
subdivided into active, chronic, or mixed types of glomerular injury. Class V was denoted 
membranous glomerulonephritis, which was subdivided into 4 subclasses: pure 
membranous nephropathy without or with mesangial hypercellularity (Va and Vb, 
respectively), membranous nephropathy with segmental endocapillary proliferation and/or 
necrosis (Vc) and membranous nephropathy with diffuse endocapillary proliferation 
and/or necrosis (Vd). Class VI was introduced to denote advanced sclerosing 
glomerulonephritis.  
The WHO system was further revised in 1995 (Churg, 1995), with the emphasis of segmental 
glomerular capillary wall necrosis to be the defining feature of class III lesions, regardless of 
the percentage of glomeruli affected. For membranous lupus nephropathy, as the long-term 
prognosis is dependent on the proliferative than membranous component, the 1995 WHO 
classification removed Vc and Vd to be included into class III and class IV lupus nephritis, 
respectively. Class V retained only the subclasses Va and Vb, under the category “diffuse 
membranous glomerulonephritis”. 
The histological classification system was modified once again in 2003 by the International 
Society of Nephrology and the Renal Pathology Society (Weening, 2004) (Table 1). One of 
the reasons was the demonstration of the poor outcome of diffuse segmental necrotizing 
glomerulonephritis involving over 50% of glomeruli, (a “severe” form of class III disease), 
as compared to class IV lupus nephritis. Class III disease referred to focal lupus nephritis, 
which was defined as involvement of less than 50% of glomeruli by segmental 
endocapillary proliferative lesions, with or without capillary wall necrosis and crescents, 
and subendothelial deposits. Class IV disease was denoted diffuse lupus nephritis which 
involved more than 50% of the glomeruli.  This class is subdivided into diffuse segmental 
lupus nephritis (class IVS) when >50% of the involved glomeruli showed segmental 
lesions, and diffuse global lupus nephritis (class IVG) when >50% of the glomeruli having 
global lesions.  The proportion of glomeruli with active and chronic lesions, fibrinoid 
necrosis or crescents, tubulointerstitial and vascular pathology should be separated 
reported.  
Class V, or membranous lupus nephritis, was defined as global or segmental continuous 
granular subepithelial immune deposits, often in the presence of concomitant mesangial 
immune deposits and hypercellularity. The distinction between pure membranous 
nephropathy and membranous nephropathy superimposed on mesangial changes was 
eliminated. When a diffusely distributed membranous lesion is associated with an active 
lesion of class III or IV, both diagnoses are reported (‘V+III’ or ‘V+IV’). Finally, minimal 
change nephropathy (class I) was renamed minimal mesangial lupus nephritis, which was 
characterized by normal light microscopy of the glomeruli with accumulation of mesangial 
immune complexes identified by immunofluorescence and/or electron microscopy. A 
complete lack of renal abnormalities by light microscopy, immunofluorescence, and electron 
microscopy no longer qualified Class I lupus nephritis. 
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Class I Minimal mesangial lupus nephritis
Normal glomeruli by light microscopy, but mesangial immune deposits by 
immunofluorescence
Class II Mesangial proliferative lupus nephritis
Purely mesangial hypercellularity of any degree or mesangial matrix 
expansion by light microsocpy, with mesangial immune deposits. A few 
isolated subepithelial or subendothelial deposits may be visible by 
immunofluorescence or electron microscopy, but not by light microscopy 
Class III 
 
 
 
 
III (A) 
III (A/C) 
III (C) 
 
Focal lupus nephritis 
Active or inactive focal, segmental or global endo- or extracapillary 
glomerulonephritis involving <50% of all glomeruli, typically with focal 
subendothelial immune deposits, with or without mesangial alterations 
 
Active lesions: focal proliferative lupus nephritis 
Active and chronic lesions: focal proliferative and sclerosing lupus nephritis 
Chronic inactive lesions with glomerular scars: focal sclerosing lupus 
nephritis
Class IV 
 
 
 
 
 
 
 
 
 
 
IV-S (A) 
IV-G (A) 
IV-S (A/C) 
 
IV-G (A/C) 
 
IV-S (C) 
 
IV-G (C) 
 
Diffuse lupus nephritis
Active or inactive diffuse, segmental or global endo- or extracapillary 
glomerulonephritis involving ≥50% of all glomeruli, typically with diffuse 
subendothelial immune deposits, with or without mesangial alterations. 
This class is divided into diffuse segmental (IV-S) lupus nephritis when 
≥50% of the involved glomeruli have segmental lesions, and diffuse global 
(IV-G) lupus nephritis when ≥50% of the involved glomeruli have global 
lesions. Segmental is defined as a glomerular lesion that involves less than 
half of the glomerular tuft. This class includes cases with diffuse wire loop 
deposits but with little or no glomerular proliferation. 
 
Active lesions: diffuse segmental proliferative lupus nephritis 
Active lesions: diffuse global proliferative lupus nephritis 
Active and chronic lesions: diffuse segmental proliferative and sclerosing 
lupus nephritis 
Active and chronic lesions: diffuse global proliferative and sclerosing 
lupus nephritis 
Chronic inactive lesions with scars: diffuse segmental sclerosing lupus 
nephritis 
Chronic inactive lesions with scars: diffuse global sclerosing lupus 
nephritis
Class V Membranous lupus nephritis
Global or segmental subepithelial immune deposits or their morphologic 
sequelae by light microscopy and by immunofluorescence or electron 
microscopy, with or without mesangial alterations. 
Class V lupus nephritis may occur in combination with class III or IV in 
which case both will be diagnosed 
Class V lupus nephritis may show advanced sclerosis
Class VI Advanced sclerotic lupus nephritis
≥90% of glomeruli globally sclerosed without residual activity 
Table 1. ISN/RPS 2003 classification of lupus nephritis 
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6. Prognosis of lupus renal disease 
Renal involvement of SLE carries significant morbidity and mortality. The renal survival 
(survival without dialysis) rates of lupus nephritis in the 1990’s range from 83-92% in 5 years 
and 74-84% in 10 years (Mok, 1999; Donadio, 1995; Bono, 1999; Neumann, 1995). The risks of 
end stage renal failure were particularly high in patients with diffuse proliferative 
glomerulonephritis, with figures ranging from 11-33% in 5 years (Mok, 1999; Dooley, 1997, 
Donadio, 1995; Neumann, 1995; Bakir, 1994; Nossent, 2000; Korbet, 2000). The prognosis of 
lupus nephritis depends on a large number of demographic, racial, genetic, histopathological, 
immunological and time-dependent factors (Mok, 2005b). Renal disease that fails to remit with 
conventional immunosuppressive therapies is a major risk factor for subsequent deterioration 
of renal function and poor outcome (Mok, 1999; Korbet, 2000; Mok, 2006b). Other unfavorable 
prognostic factors for lupus neprhitis include younger age, male sex, histological cellular 
crescents, fibrinoid necrosis, subendothelial deposits, glomerular scarring, tubular atrophy and 
interstitial fibrosis, impaired renal function at presentation, persistent hypertension, 
hypocomplementemia, low hematocrit, as well as delay in treatment due to problems of access 
to health care and poor compliance (Mok, 2005b). 
A recent hospital registry study of 5686 patients with SLE showed that there was a loss in 
life expectancy of 20 years in female and 27 years in male patients, respectively (Mok, 2011). 
Among 514 lupus deaths, direct complications of renal disease accounted for 9% of all cases 
(Mok, 2011). This reiterates that the prognosis of renal disease in SLE has yet to be improved 
by novel therapies in the future. 
7. Current treatment of lupus glomerulonephritis 
The immunosuppressive therapy of lupus nephritis is divided into an induction phase 
which targets at reducing inflammation and glomerular injury and a maintenance phase 
that aims to reduce the long-term risk of renal flares and renal function decline. Adjunctive 
therapies such as vigorous control of blood pressure to less than 120/80mmHg may retard 
the deterioration of renal function. The early use of renal protection agents such as the 
angiotensin converting enzyme inhibitors (ACEIs) and the angiotensin II receptor 
antagonists is mandatory. Hyperlipidemia should also be aggressively controlled to offer 
protection against accelerated vascular disease, especially in the membranous type of lupus 
nephritis. Calcium and vitamin D should be adequately supplemented to reduce the risk of 
aggravation of disease activity related to vitamin D deficiency, and to protect against loss in 
bone mineral density. Low-dose aspirin should be considered in patients with histological 
evidence of antiphospholipid syndrome nephropathy, although there is still no published 
evidence that this will protect against renal function decline. Anticoagulation may be 
considered in patients with persistent nephrotic range of proteinuria and the presence of the 
antiphospholipid antibodies.  
8. Induction therapy for lupus nephritis 
Milder form of lupus nephritis (ISN/RPS Class I, II) is usually manageable with 
corticosteroids (Mok, 2010b). Azathioprine (AZA) can be added as a corticosteroid sparing 
agent and for the treatment of concomitant extra-renal manifestations. Mild class V disease 
can be treated with ACEIs. Proliferative lupus nephritis (class III and IV or mixed III/V and 
IV/V) and more serious class V (nephrotic range of proteinuria or deteriorating renal 
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function) disease requires more aggressive induction regimens consisting of corticosteroids 
and a non-corticosteroid immunosuppressive agent. 
The standard therapy for severe proliferative lupus nephritis has been a combination of high-
dose glucocorticoid and cyclophosphamide (CYC). From the series of randomized controlled 
trial conducted by the National Institute of Health (NIH), it was demonstrated that prednisone 
combined with intravenous (IV) pulse CYC offered better long-term protection against renal 
function decline than prednisone alone (Austin, 1986; Gourley, 1996; Illei, 2001). However, the 
use of CYC is associated with a number of untoward side effects, which include infection, 
ovarian and bladder toxicities, leukopenia, increased risk of cervical intraepithelial neoplasia 
and malignancy. Some of these toxicities are dose dependent, with a higher risk related to a 
higher cumulative dose (Mok, 1998). IV pulse CYC has gained popularity over continuous 
daily oral CYC because it is associated with less toxicity on the bladder and the gonads. 
Whether oral CYC is more efficacious than IV pulse CYC in lupus nephritis remains 
controversial because of the lack of large controlled trials (Austin, 1986; Mok, 2001). A recent 
analysis of a large cohort of patients with diffuse proliferative lupus nephritis showed a trend 
of better efficacy of oral CYC than IV pulse CYC in preserving renal function after a mean 
follow-up of 8.8 years (Mok, 2006b). In a multivariate model, the cumulative dose of CYC 
delivered instead of the route of CYC was an independent factor for a complete renal 
response. This suggests that the higher potency of the oral CYC regimen is probably related to 
the higher cumulative dose delivered instead of the route of administration per se. However, 
ovarian toxicity leading to premature menopause was more frequent in users of oral CYC. 
Although the optimal route of CYC and duration of therapy in lupus nephritis remains to be 
defined, recent evidence supports the use of a shorter course and lower dose of CYC to 
minimize toxicities (Mok, 2001; Mok, 2002; Houssiau, 2010a). Houssiau et al. (2010a) 
compared the efficacy and toxicity of two less intensive intravenous pulse CYC regimens for 
the initial treatment of lupus nephritis.  Eighty-four patients (predominantly Caucasians) 
were randomized to receive either 8 intravenous pulses of CYC (0.5g/m2 to a maximum of 
1.5gm) or 6 biweekly low dose pulses of CYC (500mg each). In both regimens, CYC was 
later substituted with AZA for long-term maintenance. Patients who participated in the 
study had milder renal disease compared to other lupus nephritis trials, as reflected by a 
lower proportion of patients having class IV disease, nephrotic syndrome and renal function 
impairment. After 10 years, rates of mortality, sustained doubling of serum creatinine and 
end stage renal disease did not differ between the two groups (36). The incidence of 
cardiovascular events and was also similar. Cancers, however, were numerically more 
common in patients who had received the low-dose regimen. Thus, for less serious lupus 
nephritis, a low-dose CYC regimen, followed by AZA is a viable strategy if there are no 
alternatives to CYC for initial treatment. 
Nevertheless, CYC remains the treatment of choice for high-risk patients with proliferative 
lupus nephritis such as those with impaired or rapidly deteriorating renal function, 
histological cellular crescents or a combination of high activity and chronicity scores (Tang, 
2009). The course of CYC should be limited to less than 6 months, with subsequent replacement 
by another immunosuppressive agent, to reduce the incidence of toxicities (Mok, 2002). 
9. Recent controlled trials for induction therapy of severe lupus nephritis 
Six randomized controlled trials comparing the efficacy and adverse effects of different 
treatment protocols for the induction therapy of severe lupus nephritis have recently been 
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presented (Appel, 2009; Grootscholten, 2006, Bao, 2008; Chen, 2011; Mok, 2008; Furie, 2009). 
These are briefly summarized in Table 2. 
In the largest lupus nephritis controlled trial to-date, called the Aspreva Lupus Management 
Study (ALMS), 370 patients with histologically ISN/RPS class III, IV or V lupus nephritis 
were randomized to receive either monthly IV pulse CYC (0.5-1.0g/m2) or MMF (target 
3g/day) on top of high-dose prednisone (60mg/day initially and then tapered) (Appel, 
2009). Two-third of the participants had class IV disease. Asians and Hispanics comprised 
33% and 35% of the participants, respectively. Three hundred and six (83%) patients 
completed the 24-week protocol. Clinical response, defined by a decrease in urine 
protein/creatinine ratio (P/Cr) to <3 in patients with baseline nephrotic range P/Cr 3, or 
by 50% in patients with subnephrotic baseline P/Cr (<3), and stabilization (25%) or 
improvement in serum creatinine at 24 wk as adjudicated by a blinded clinical endpoints 
committee, was not significantly different between the CYC (53%) and MMF (56%) group. 
Subgroup analyses revealed that MMF was associated with a significantly higher response 
rate than CYC (60% vs 39%; p=0.03) in the non-Caucaisan non-Asians, which were mainly 
Hispanics. The rates of adverse events and serious adverse events were not significantly 
different between the two groups. Specifically, nausea, vomiting and alopecia were 
numerically more frequent in the CYC group, whereas diarrhea was more commonly 
reported in the MMF group. The induction phase of the ALMS study did not allow 
comparison of long-term side effects such as sustained amenorrhea and malignancies. There 
were 9 and 5 deaths in the MMF and CYC group, respectively. Of the 9 deaths in the MMF 
group, 7 were Asians (mainly Chinese), suggesting that Asian patients tolerated high-dose 
prednisone and MMF (3g/day) less well.  
A controlled trial comparing the efficacy of CYC and azathioprine (AZA) in lupus nephritis 
was reported by Grootscholten et al. (2006). In this study, 87 patients with proliferative 
lupus nephritis (class III and IV) were randomized to receive either oral prednisone 
combined with intravenous pulse CYC (750mg/m2 monthly for 6 months and then quarterly 
for another 7 doses) or intravenous pulse methylprednisolone (1 gram daily for 3 days for 9 
pulses) together with AZA (2mg/kg/day). At the end of the third year, both groups of 
patients received AZA for long-term maintenance (2mg/kg/day). The dosage of AZA was 
reduced to 1mg/kg/day after 4 years of treatment. This cohort of patients consisted mainly 
of Caucasian patients (76%) who had serious renal disease as evidenced by a high 
proportion of patients having hypertension (57%), nephrotic syndrome (53%) and impaired 
creatinine clearance (56%) at presentation. In the first 2 years, no significant difference in the 
rates of complete and partial renal remission could be demonstrated between the two 
regimens. After a median follow-up of more than 5 years, significantly more patients in the 
AZA arm relapsed and there was a trend of higher incidence of doubling of serum 
creatinine in the AZA-treated patients. Interestingly, the incidence of herpes zoster infection 
was lower in the CYC than AZA arm during the first two years of treatment. 
Although this was a randomized controlled trial, the number of patients assigned to the two 
treatment arms was unequal (50 patients in the CYC arm vs 37 patients in the AZA group). 
The corticosteroid regimens of the two treatment arms were also different, which 
confounded a proper interpretation of whether CYC was more effective than AZA by its 
own.  However, taking the observation that relapse of nephritis and renal function decline 
was more common in AZA-treated patients despite the use of a more intensive 
corticosteroid regimen, it was not unreasonable to conclude for the superiority of CYC over 
AZA in the treatment of severe lupus nephritis. 
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Author,  
year 
N 
Study 
duration
Histological 
classes of 
lupus 
nephritis
Steroid 
regimen 
Comparators
Primary 
end points 
Adverse 
events 
Houssiau, 
2010a 
84 10 yrs 
WHO III, IV, 
Vc,Vd 
Prednisolone 
(0.5mg/kg/d) for 
4wks, then taper 
to 5-7.5mg/d for 
at least 30mths  
IV CYC (0.5g/m2 to 
a max of 1.5g) 
monthly for 8 doses 
vs 6 biweekly low 
dose pulses of 
500mg, followed by 
AZA in both 
Rates of 
mortality, 
sustained 
doubling of 
serum 
creatinine and 
end stage renal 
disease similar 
between the 
two groups 
Cardiovascular 
events similar; but 
cancers were 
numerically more 
common in the 
low dose CYC 
group 
Appel, 
 2009 
370 24 wks 
ISN/RPS 
III,IV,V 
Prednisolone 
60mg/day then 
taper 
IV CYC (0.5-
1.0g/m2) monthly 
for 6 doses vs MMF 
(3g/d) 
Clinical 
response 
similar at 6 
months; MMF 
higher reponse 
rate than CYC 
in non-
Caucasians 
non-Asians 
Nausea, vomiting 
and alopecia more 
common in CYC 
group; diarrhea 
more common 
with MMF; 
numerically more 
deaths in MMF 
group 
Grootscholten, 
2006 
87 5.7 yrs 
WHO III, IV, 
Vc, Vd 
Prednisone 
1mg/kg/day, 
tapered to 
10mg/d after 6 
mths vs IV MP 
for 9 doses + 
prednisone 
20mg/d and 
taper  
IV CYC 
(750mg/m2) 
monthly for 6 then 
3-monthly for 
another 7 doses 
followed by AZA vs 
AZA (2mg/kg/d) 
following pulse MP
Complete and 
partial response 
rate similar at 2 
years; at 5 
years, 
significantly 
more relapses 
in AZA group 
with a higher 
incidence of 
doubling of 
serum 
creatinine 
More herpes 
zoster in the AZA 
group than CYC; 
major infection 
rate similar; more 
ovarian toxicities 
in the CYC-
treated patients 
Bao,  
2008 
40 9 mths Mixed IV+V
Pulse MP 
(0.5g/day x 3d) + 
prednisolone 
(0.6-
0.8mg/kg/day) 
then taper 
IV CYC (0.5-
1g/m2/ monthly 
for 9 months) vs 
MMF (1g/d) + Tac 
(4mg/d) 
Complete 
response rate 
significantly 
higher in MMF 
+ Tac than 
CYC group at 6 
and 9 mths 
Gastrointestinal 
upset, leucopenia, 
alopecia, 
menstrual 
irregularities and 
upper respiratory 
tract infection 
more common in 
CYC group 
Chen,  
2011 
81 6 mths 
ISN/RPS 
III,IV,V 
Prednisolone 
(1mg/kg/d) then 
taper 
IV CYC (0.5-
1g/m2/ monthly 
for 6 months) vs Tac 
(0.05mg/kg/d) 
titrating to a level of 
5-10ng/ml 
Clinical 
response at 6 
months similar 
between the 
two groups 
Infection rate 
similar; more 
leucopenia and 
gastrointestinal 
upset with CYC 
Mok, 
 2008 
130 6 mths 
ISN/RPS 
III,IV,V 
Prednisolone 
(0.6mg/kg/d) 
then taper 
MMF (2-3g/d) vs 
Tac (0.1-
0.06mg/kg/d) 
Clinical 
response 
similar at 6 
months 
Herpes zoster 
more common 
with MMF; 
alopecia, tremor 
and reversible 
increase in serum 
creatinine more 
common with Tac 
Furie,  
2009 
144 52 wks 
ISN/RPS 
III,IV 
High-dose 
prednisone 
MMF (2-3g/d) in 
both; rituximab x 2 
courses (1g x2 each 
course) vs placebo 
Clinical 
efficacy similar 
at 52 wks 
Infection rate and 
major infection 
rate similar 
between the two 
groups 
Yrs = years; mths = months; CYC = cyclophosphamide; MMF = mycophenolate mofetil;  
AZA = azathioprine; Tac = tacrolimus 
Table 2. Recent randomized controlled trials of induction therapy for lupus nephritis 
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Bao et al. (2008) studied 40 patients with mixed proliferative and membranous lupus nephritis 
(ISN/RPS IV+V) by randomizing them to receive either IV pulse CYC (0.5-1g.m2 monthly) 
(N=20) or low-dose combination of MMF (500mg BD) and tacrolimus (Tac) (2mg BD) (N=20), 
on top of high-dose prednisolone (0.6-0.8mg/kg/day) after 3 daily pulses of 
methylprednisolone (0.5g). The mean creatinine clearance at recruitment was 97.6ml/min and 
85% patients had normal serum creatinine level. At 6 months, the rate of complete response, 
defined as daily proteinuria <0.4g/day with normal urinary sediments and stabilization of 
serum creatinine (<15% increase), was significantly higher in the MMF / Tac group (50%) than 
the CYC group (5%). The corresponding rates at 9 months of treatment were 65% and 15%, 
respectively. Leukopenia, gastrointestinal upset, upper respiratory tract infection, alopecia and 
irregular menses were more common in the CYC than MMF/Tac group of patients. 
A randomized controlled trial comparing the short-term efficacy of IV pulse CYC with 
tacrolimus (Tac) in lupus nephritis were recently presented (Chen, 2011). In this study, 81 
patients with class III, IV or V lupus nephritis were randomized to receive IV pulse CYC 
(0.5-1g.m2 monthly) (N=39) or Tac (0.05mg/kg/day titrating to a level of >5ng/mL) (N=42) 
in combination with high-dose prednisolone (1mg/kg/day). The study population 
consisted of moderate to high-risk patients as shown by a high proportion of class IV 
disease (77%) and impaired renal function (11%) at presentation. At 6 months, the rate of 
complete remission, which was defined as proteinuria <0.3g/day, stabilization of serum 
creatinine and normalization of urinary sediments, was not significantly different between 
the CYC and Tac group of patients (38% vs 52%, p=0.2). Regarding adverse events, 
gastrointestinal upset and leucopenia were significantly more frequent in the CYC group 
but the rate of infection was similar between the CYC- and Tac-treated patients. Transient 
increase in serum creatinine was reported in 8% of patients receiving Tac. 
Our group has conducted a controlled trial comparing the efficacy of MMF (2g/day, 
titrating to 3g/day if response suboptimal at 3 months) with Tac (0.1mg/kg/day in first 2 
months with tapering to 0.06mg/kg/day) in combination of high-dose prednisolone 
(0.6mg/kg/day for 6 weeks and taper) for lupus nephritis (Mok, 2008). Up to March 2011, 
130 patients with ISN/RPS class III, IV or V lupus nephritis were recruited. Our preliminary 
analysis showed that the clinical complete and partial response rates were not significantly 
different between the two treatment arms at month 6. The rate of infection, in particular 
herpes zoster reactivation, was higher in MMF than Tac-treated patients, whereas alopecia, 
tremor and reversible increase in serum creatinine was more frequent in the Tac group of 
patients. Dose-related neurological and metabolic adverse effects of Tac, and the possibility 
of early renal relapse upon completion of the induction phase and substitution of Tac have 
to be carefully monitored. 
The LUNAR study is a phase III randomized, double-blind, placebo-controlled multicenter 
study to evaluate the efficacy and safety of rituximab in patients with active proliferative 
lupus nephritis (Furie, 2009). Patients with ISN/RPS Class III or IV lupus nephritis and 
urine protein to creatinine (UP/Cr) ratio >1 were randomized to receive rituximab (1000mg) 
or placebo infusion on days 1, 15, 168 (week 24) and 182 (week 26), on top of corticosteroid 
and MMF (>2g/day). Seventy-two patients were recruited in each treatment arm. Two-third 
of the patients had class IV nephritis and the mean UP/Cr at entry was 4.0±2.8. At week 52, 
no statistically significant differences in the primary and secondary endpoints were 
observed between the rituximab and placebo groups of patients, although there were 
numerically more responders in the rituximab group (57% vs 46% in the placebo group). 
Africans and Hispanics treated with rituximab tended to have better response compared to 
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placebo than the Whites. Rituximab had a greater effect than placebo on anti-dsDNA and 
complement levels at week 52. Serious adverse events and infection rates were similar 
between the two groups but two deaths occurred in the rituximab-treated patients. 
Taken the evidence from these recent studies together, it appears that MMF should be used 
as the first line treatment in combination with corticosteroids for severe lupus nephritis 
because of its stronger evidence (largest sample size) compared to other agents and lower 
incidence of toxicities compared to conventional CYC. Although Tac has similar efficacy 
with either CYC or MMF, it has been tried in a smaller population of patients and 
disadvantages such as transient and long-term nephrotoxicity, as well as higher relapse rate 
upon substitution with another immunosuppressive agent are of concern. However, Tac is a 
definite option when patients are contraindicated for or intolerant to MMF. Moreover, Tac is 
indicated as salvage therapy for refractory lupus nephritis. Tac is preferred to cyclosporin A 
for the lower incidence of cosmetic side effects. The initial results of the B cell depleting 
agents such as rituximab are disappointing. Although evidence does not support an 
additional benefit of rituximab on top of MMF treatment for lupus nephritis, rituximab is an 
option to be considered in recalcitrant lupus nephritis, as evidenced by a number of 
uncontrolled case series (Jonsdottir, 2010; Melander, 2009; Vigna-Perez, 2006).  
10. Maintenance therapy for lupus nephritis 
There are no randomized controlled trials with the main objective of delineating whether 
maintenance therapy of lupus nephritis is effective or not. However, some indirect evidence 
suggests that maintenance therapy is probably necessary in severe lupus nephritis. In a 
long-term follow-up of 145 patients who participated in the NIH lupus nephritis studies, 
renal flares occurred in 45% of the patients when immunosuppression was completely 
stopped (Illei, 2002). A recent retrospective review of 32 patients with predominantly diffuse 
proliferative lupus nephritis described a relapse of lupus activity in 53% of patients after 
immunosuppression was discontinued (Moroni, 2006). In our experience with 212 patients 
with diffuse proliferative lupus nephritis (Mok, 2006b), despite maintenance treatment was 
given to 73% of patients, more than one-third of patients still had renal flares which might 
be serious. The use of maintenance therapy for more than 3 years was independently 
associated with an increased likelihood of having the composite outcome of doubling of 
serum creatinine, end stage renal failure or death (hazard ratio 4.62 [1.35-15.8]; p=0.02).  
In a 2006 retrospective review of 32 patients with proliferative lupus nephritis in whom 
immunosuppressive therapy was stopped for a median of 203 months, clinical remission 
persisted in 47% of patients (Moroni, 2006). Patients who experienced sustained remission had 
received a longer total median duration of immunosuppressive treatment since renal biopsy 
than those who did not experience remission (median 57 months vs 30 months; p<0.01). This 
finding, coupled with the observation that maintenance treatment for less than 3 years after 
successful cyclophosphamide induction was a predictor of poor renal outcome in proliferative 
lupus nephritis (Mok, 2006b), suggests that maintenance immunosuppressive therapy should 
be continued for at least 3 years after a complete clinical response is achieved. 
Four recent randomized controlled trials compare the efficacy of different immunosuppressive 
agents in maintaining remission in lupus nephritis (summarized in Table 3). Contreras et al. 
(2004) randomized 59 patients with lupus nephritis (mainly African and Hispanic Americans; 
78% had class IV disease) to receive one of the three treatment arms after induction with 4-7 
pulses of intravenous CYC: (1) MMF (0.5-3g/day); (2) quarterly pulse CYC; (3) AZA (1-
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3mg/kg/day). Long-term observation showed that either MMF or AZA was superior to CYC 
in the prevention of the composite outcome of renal failure and death. MMF was more 
efficacious than pulse CYC in the prevention of renal flares. Moreover, maintenance treatment 
with CYC was associated with more side effects such as nausea, vomiting and infection. 
Although the sample size is small, this study shows that maintenance treatment of lupus 
nephritis with either AZA or MMF is safe and effective. However, whether MMF is more cost-
effective than AZA is not clear because significant difference in all outcomes is not apparent 
between MMF- and AZA-treated patients. Moroni et al. (2006) studied 69 patients (mainly 
Caucasians) with lupus nephritis and compared the efficacy of cyclosporin A (CSA) with AZA 
for maintenance therapy. After initial induction treatment with pulse methylprednisolone, 
prednisone and oral CYC (91.523.8 mg/day for a median of 3 months), patients were 
randomized to receive either cyclosporin A (Neoral; 4.0 to 2.5-3.0mg/kg/day) (N=36) or AZA 
(2mg/kg/day) (N=33) for maintenance. At 4 years of follow-up, flare occurred in 24% of AZA-
treated and 19% of CSA-treated patients, respectively (no significant difference). Minor 
infections and leucopenia were more commonly reported with AZA treatment whilst 
arthralgia and gastrointestinal symptoms were more common in CSA-treated patients. 
 
Author, 
year 
N 
Follow-
up 
duration
Histological 
classes of lupus 
nephritis
Induction 
regimen
Comparators
Primary end 
points 
Adverse events 
Contreras, 
2004 
59 
Beyond 5 
yrs 
WHO III, IV, Vb
IV CYC (0.5-
1g/m2) for 4-
7 pulses 
IV CYC (0.5-1g/m2) 
every 3 months vs 
MMF (0.5-3g/d) vs 
AZA (1-3mg/kg/d)
Renal flare and 
renal function 
deterioration was 
significantly more 
common with CYC 
than MMF; MMF no 
better than AZA in 
the above outcomes 
Nausea, vomiting, 
major infection rate 
and sustained 
amenorrhea more 
common with CYC 
than the other 2 
groups 
Moroni, 
2006 
69 4 yrs 
Class IV 
nephritis 
Pulse MP + 
high dose 
prednisone + 
oral CYC for 
3 mths 
CSA (4mg/kg/d) 
and taper to 2.5-
3mg/kg/d vs AZA 
2mg/kg/d 
7 flares in CSA (19%) 
vs 8 flares in AZA 
(24%) group; 
reduction in 
proteinuria, blood 
pressure and 
creatinine clearance 
similar in both 
groups 
Gum hypertrophy, 
hypertrichosis, 
hypertension, 
arthralgia, 
gastrointestinal 
symptoms more 
common with CSA; 
Infections and 
leucopenia more 
common with AZA 
Houssiau, 
2011 
105 53 mths
WHO class III, 
IV, Vc, Vd 
Pulse MP + 
high dose 
prednisone + 
IV CYC 
(500mg) x 6 
doses 
AZA (2mg/kg/d) 
vs MMF (2g/d) 
Frequency of renal 
and extra-renal 
flares, doubling of 
serum creatinine 
similar in both 
groups 
Infection rate similar; 
but drug-related 
cytopenias more 
common with AZA; 
withdrawal due to 
pregnancy wish 
more common with 
MMF 
Wofsy, 
2010 
227 2.1 yrs 
ISN/RPS 
III,IV,V 
High dose 
prednisone + 
either IV CYC 
(6 pulses) or 
MMF (3g/d) 
x 6 mths 
AZA (2mg/kg/d) 
vs MMF (2g/d) 
Treatment failure, 
defined as the 
composite outcome 
of renal flares, 
doubling of serum 
creatinine or end 
stage renal failure, 
death or need for 
rescue therapy 
significantly less 
common in MMF 
than AZA group
No information yet 
Yrs = years; mths = months; CYC = cyclophosphamide; MMF = mycophenolate mofetil;  
AZA = azathioprine; CSA = cyclosporin A 
Table 3. Recent randomized controlled trials of maintenance therapy for lupus nephritis 
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In the MAINTAIN study conducted by Houssiau et al. (2010b), 105 patients with class III, 
IV, Vc and Vd lupus nephritis were randomized to receive either MMF (2g/day) (N=53) or 
AZA (2mg/kg/day) (N=52) after an initial induction regimen that consisted of IV pulse 
methylprednisolone, high-dose prednisone and IV pulse CYC (500mg 2-weekly for 6 doses). 
Participants were mainly Caucasians and 10% of patients had impaired renal function at 
study entry. After a mean follow-up of 53 (15-65) months, 24 (23%) patients withdrew from 
the study mainly because of pregnancy wish (in the MMF group) and adverse effects. 
Frequency of renal and extra-renal flares, doubling of serum creatinine and incidence of 
infections occurred at similar frequency in the two arms. However, drug-related cytopenias 
were more common with AZA. 
Results of the maintenance phase of the ALMS study was released in the 9th International 
Lupus Congress at Vancouver in 2010 (Wofsy 2010). Two hundred and twenty-seven 
patients who had completed the induction phase of the ALMS (IV pulse CYC or MMF 
3g/day) were randomized to receive either MMF (2g/day) (N=116) or AZA (2mg/kg/day) 
(N=111) for maintenance treatment. The mean daily doses received by the patients were 
1.870.43g and 12048mg, respectively, for MMF and AZA. After a mean follow-up of 2.1 
years, the rate of treatment failure, defined as renal flare, doubling of serum creatinine or 
end stage renal disease, need for rescue therapy or death, was significantly less common in 
MMF than AZA-treated patients. The results were similar in patients induced by CYC or 
MMF at recruitment. 
Taken these studies together, it appears that MMF is the preferred agent for long-term 
maintenance therapy for lupus nephritis. However, the cost-effectiveness of this approach 
has to be evaluated in future analysis. AZA and CSA are alternative options for patients 
who are intolerant to MMF or plan for pregnancy. The long-term use of the calcineurin 
inhibitors such as Tac and CSA is not encouraged because of the increased risk of 
nephrotoxicity, hyperlipidemia and atherosclerosis. 
11. Membranous lupus nephropathy 
Membranous lupus nephropathy (MLN), defined as global or segmental continuous 
granular subepithelial immune deposits, often in the presence of mesangial immune 
deposits and mesangial hypercellularity, comprises only one-fifth of all cases of 
histologically confirmed lupus nephritis (Mok, 2009). Reported rates of patient survival and 
end-stage renal disease in MLN vary considerably, because of substantial heterogeneity 
among the published studies. The risk of progression of MLN to renal failure is generally 
reduced in the absence of proliferative lesions, but patients are nevertheless at risk of 
thromboembolic complications.  
The optimal therapy for MLN remains elusive because of the paucity of clinical trials. Mixed 
membranous and proliferative lupus nephritis should be treated in the same way as pure 
proliferative lupus nephritis. If MLN is not accompanied by proliferative lesions but is 
associated with clinically relevant proteinuria, renal insufficiency or failure to respond to 
supportive therapies, immunosuppressive treatment is indicated. In addition, 
cardiovascular protection and blockade of the renin-angiotensin system should be instituted 
early in all patients. 
Austin et al. (2009) randomized 42 patients (71% Blacks or Hispanics) with MLN to receive one 
of the following regimens: (1) alternate day prednisone (1mg/kg/day for 8 weeks and taper to 
0.25mg/kg/day throughout); (2) similar prednisone regimen plus IV pulse CYC (0.5-1.0g/m2 
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every two months); or (3) similar prednisone regimen plus CSA (5mg/kg/day). At 12 months, 
the cumulative probability of complete (<0.3g/day proteinuria) or partial (<2.0g/day 
proteinuria or improvement by 50% from baseline) remission was highest with CSA (83%), 
followed by IV pulse CYC (60%) and prednisone alone (27%).  The response rates of either 
CSA or CYC were significantly better than prednisone alone. However, relapse of nephrotic 
syndrome was significantly more common after discontinuation of treatment with CSA than 
IV pulse CYC. Adverse effects during the 12-month period included insulin-requiring diabetes 
(one with prednisone and two with CsA), pneumonia (one with prednisone and two with 
CsA), and localized herpes zoster (two with IVCY). 
A recent pooled analysis of 65 patients with pure membranous lupus nephritis recruited for 
two randomized controlled trials and completed 24 weeks of treatment (Ginzler, 2005; 
Appel, 2009) showed that there were no differences in the measured end points, response 
rate, mortality and withdrawal rate between MMF and IV pulse CYC (Radhakrishnan, 
2010). There was also no difference in the change in proteinuria or partial response rate 
between MMF and CYC in those patients presenting with nephritic syndrome.  
Therefore, similar to the proliferative types of lupus nephritis, more serious MLN should be 
treated with a combination of glucocorticoids and non-glucocorticoid immunosuppressive 
agent. A number of uncontrolled series have reported efficacy of various regimens for MLN 
such as AZA, tacrolimus and MMF in combination with glucocorticoids (Mok, 2009). Taken 
these together, possible options for MLN include MMF, IV pulse CYC, CSA, AZA and 
tacrolimus. Many specialists will start with MMF or AZA for their lower incidence of 
adverse effects, reserving other agents for salvage therapy when the clinical response is not 
optimal. Controlled trials comparing existing immunosuppressive agents and experimental 
modalities such as rituximab, infliximab and sirolimus should be undertaken in the future 
(Jonsdottir, 2011). 
12. Refractory lupus nephritis 
There is no international consensus on the definitions of remission and treatment 
refractoriness in lupus nephritis. In the absence of reliable and readily available biomarkers 
for ongoing activity / inflammation in the kidneys and histological / immunological data 
from routine post-therapy renal biopsy, true remission of lupus nephritis is difficult to 
define. Despite the discrepancies in the clinical criteria used, up to 20% of patients with 
lupus nephritis are reported to be resistant to initial immunosuppressive therapy (Mok, 
2006a). They are more likely to be patients with multiple unfavorable prognostic factors 
such as the African ethnicity, delayed institution of CYC, poor treatment compliance, 
impaired serum creatinine, severe nephrotic syndrome, arterial hypertension at 
presentation, and the presence of active crescents and a higher degree of chronicity in renal 
histology (Mok, 2005b).  
Using the similar renal response criteria as suggested by the NIH investigators (Boumpas, 
1998), we reported that 14% of a cohort of 212 patients with diffuse proliferative lupus 
nephritis did not respond to either continuous oral or intermittent pulse CYC therapy at the 
end of the induction courses (Mok, 2006b). The failure to respond to immunosuppressive 
treatment in the first year is associated with increased risk of renal function decline and the 
development of end stage renal disease (Mok, 1999). 
Controlled trials in refractory lupus nephritis are unavailable. Open-labeled studies have 
reported success of newer immunosuppressive drugs, immunomodulatory therapies and 
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the biological agents such as MMF, calcineurin inhibitors (CSA and tacrolimus), 
leflunomide, intravenous immunoglobulin, immunoadsorption and rituximab in the 
treatment of CYC-refractory lupus nephritis. More aggressive CYC regimens such as daily 
oral CYC and the immunoablative CYC protocol have been used in lupus nephritis, but at 
the expense of more toxicities (Petri, 2010). Novel biological agents that are undergoing 
clinical trials in renal and non-renal lupus include epratuzumab, ocrelizumab, belimumab, 
abatacept and atacicept (summarized in Table 4) (Mok, 2010c). 
 
B cell depletion 
Fludarabine, rituximab, epratuzumab, ocrelizumab, belimumab, atacicept 
B cell tolerization 
Abetimus sodium 
Blockade of the co-stimulatory pathways 
Abatacept (CTLA4-Ig) 
Neutralization of cytokines 
IL-10, TNF, IL-6, type I interferons 
Anti-complement 
anti-C5b (eculizumab) 
Table 4. Biological therapies for renal and non-renal lupus 
13. Biomarkers for lupus nephritis 
Current laboratory markers for lupus nephritis such as proteinuria, urine protein-to-
creatinine ratio, creatinine clearance, anti-dsDNA and complement levels are unsatisfactory. 
They lack sensitivity and specificity for differentiating renal activity and damage in lupus 
nephritis. Significant kidney damage can occur before renal function is impaired and first 
detection by laboratory parameters. Persistent proteinuria may not necessarily indicate 
ongoing inflammation in the kidneys; and may be contributed by pre-existing chronic 
lesions or recent damage in the kidneys during the course of the disease. Flares of nephritis 
can occur without any observable and recent increase in the degree of proteinuria. Renal 
biopsy is the gold standard for providing information on the histological classes of lupus 
nephritis and the relative degree of activity and chronicity in the glomeruli. However, it is 
invasive and serial biopsies are impractical in the monitoring of lupus nephritis. Thus, novel 
biomarkers that are able to discriminate lupus renal activity and its severity, predict renal 
flares, monitor treatment response and disease progress, and stratify prognosis are 
necessary. 
A biomarker refers to a biologic, biochemical or molecular event that can be assayed 
qualitatively and quantitatively by laboratory techniques. An ideal biomarker for lupus 
nephritis should possess the following properties: (1) Good correlation with renal activity as 
reflected by the degree of proteinuria and urine sediments; (2) Sensitive to change so that it 
can be used for serial monitoring of disease activity in the kidneys and defining treatment 
response and clinical remission; (3) Ability to predict renal activity / flares before an 
obvious change in conventional clinical parameters occurs so that early treatment / 
preventive strategies can be considered; (4) Specific to nephritis among patients with SLE; 
and (5) Specific to SLE for aiding early diagnosis of lupus nephritis. In addition, a useful 
biomarker should be easy to assay, simple to interpret and readily available in most 
laboratories with a reasonable cost. 
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Hitherto, quite a number of serum and urine biomarkers have been studied in lupus 
nephritis (summarized in Table 5). Many of these markers have only been tested in cross-
sectional studies with small sample size, and none has been rigorously validated in large-
scale longitudinal cohorts of patients with different ethnic background. It is unlikely at this 
juncture that a candidate biomarker stand-alone can replace conventional clinical 
parameters to monitor disease progress and detect early renal flares. Urine biomarkers 
appear to be more encouraging than serum biomarkers possibly because they are the direct 
products or consequences of kidney inflammation or injury. Future directions in SLE 
biomarker research should focus on a combination of novel markers with conventional 
clinical parameters to enhance the sensitivity and specificity for the prediction of renal flares 
and prognosis in lupus nephritis (Mok, 2010a). 
 
Urinary monocyte chemoattractant protein-1 (uMCP-1)
Plasma and urine neutrophil gelatinase–associated lipocalin (NGAL) 
Urinary tumor necrosis factor (TNF)-like inducer of apoptosis (uTWEAK) 
Urine proteomics 
Hepcidin 
Anti-C1q antibodies 
Anti-nucleosome antibodies 
Anti--actinin antibodies 
MAGE-B2 antibodies 
Anti-CRP antibody 
Serum and urine IL-12 
Peripheral blood leukocyte chemokine transcriptional levels 
Serum apoCIII 
Serum ICAM-1 
Anti-endothelial cell antibody 
Urine osteoprotegerin (OPG) 
FOXP3 mRNA expression in urinary sediments 
Urine endothelin-1 
Urine CXCR3+CD4+T cells 
Urine VCAM-1, P-selectin, TNFR-1 and CXCL16 
Urine TGF-1 
TGF and MCP-1 mRNA expression in urine sediments 
Chemokine and growth factor mRNA level in urinary sediments 
Serum nitrate and nitrite level 
Anti-ribosomal P antibody 
Urine glycoprotein panel
Table 5. Novel biomarkers for lupus nephritis 
14. Conclusions 
Renal involvement is a major determinant of the prognosis of SLE. Lupus renal disease is 
more frequent in certain ethnic groups such as the Africans, Hispanics and Asians. Of the 
various histological types of lupus nephritis, diffuse proliferative lupus nephritis carries the 
worst prognosis. Treatment of lupus nephritis should target at disease remission, prevention 
of relapse and complications, and long-term preservation of renal function. The main stay of 
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treatment of lupus nephritis is immunosuppression using a combination of high-dose 
glucocorticoid and a non-glucocorticoid immunosuppressive agent. Mycophenolate mofetil 
combined with prednisone has emerged to be the standard regimen. Intravenous pulse or 
daily oral cyclophosphamide is reserved for more serious or refractory cases of lupus 
nephritis. The evidence for calcineurin inhibitors in lupus nephritis is less strong and these 
agents are reserved for patients intolerant or recalcitrant to standard therapies. B cell 
modulation is emerging as novel therapeutic modalities for lupus nephritis. While further 
evidence from controlled trials is eagerly awaited, the current use of B cell modulating 
agents is confined to recalcitrant lupus renal disease. Conventional markers for activity of 
lupus nephritis are neither sensitive nor specific. Novel biomarkers are being studied for 
earlier detection of renal flares and better prognostic stratification so that intervention can 
be instituted early to minimize damage to renal function.  
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